**Title:** Dual Src and EGFR Inhibition in Combination with Gemcitabine in Advanced Pancreatic Carcinoma: Phase I Results

Journal Name: Investigational New Drugs

**Authors:** Dana B. Cardin, MD<sup>1,2</sup>, Laura W. Goff, MD<sup>1,2</sup>, \*Emily Chan, MD, PhD<sup>3</sup>, Jennifer G. Whisenant, PhD<sup>1,2</sup>, G. Dan Ayers, MS<sup>4,5</sup>, Naoko Takebe, MD, PhD<sup>6</sup>, Lori R. Arlinghaus, PhD<sup>7</sup>, Thomas E. Yankeelov, PhD<sup>8</sup>, Jordan Berlin, MD<sup>1,2</sup>, Nipun Merchant, MD<sup>9</sup>

<sup>1</sup>Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA <sup>2</sup>Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA <sup>3</sup>Amgen Inc., Thousand Oaks, CA, USA

<sup>4</sup>Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA

<sup>5</sup>Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN, USA

<sup>6</sup>Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA


<sup>7</sup>Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA

<sup>8</sup>Institute for Computational and Engineering Sciences, Departments of Biomedical Engineering and Diagnostic Medicine, Livestrong Cancer Institutes, University of Texas, Austin, TX, USA <sup>9</sup>Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA

## Please address correspondence to:

Dana B. Cardin, MD dana.cardin@vanderbilt.edu

**Supplemental Figure 1: CA19-9 levels correlate with changes in tumor size.** Moderate and significant positive correlation (Pearson Correlation = 0.65, p=0.023) observed between changes in CA19-9 levels at four weeks and tumor size at eight weeks.



1